Indeed, it seems that increased sensitivity to PI3K/Akt pathway inhibitors is not universal to all types of cancer or to all classes of inhibitors, and the presence of different PIK3CA mutations might lead to distinct inhibitor sensitivities [161,168,170,177,182,185,192,193,205,206,207]. This evidence concerns the gene AKT1 and cancer.